Belantamab Mafodotin Offers New Options for Patients with Multiple Myeloma

The drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy.

In a recent interview with Pharmacy Times, Robert Mancini, PharmD, BCOP, FHOPA, said the recent FDA approval of belantamab mafodotin has provided a much-needed new option for patients with multiple myeloma.

Mancini said the drug is approved for patients after 4 or more failed lines of therapy, although many patients in clinical trials had received 7 or more prior lines of therapy. Although he said this approval does not entirely shift the treatment landscape for multiple myeloma, Mancini said this approval can offer extended survival for patients with the incurable disease.